NY-XYLEM
31.5.2022 09:02:08 CEST | Business Wire | Press release
Premier League Champions Manchester City today announced the renewal of its multi-year global partnership with water technology leader, Xylem (NYSE:XYL). The renewed partnership includes the Manchester City men’s and women’s teams, and MLS Champions New York City FC and Mumbai City, who are part of City Football Group (CFG). Through the partnership to date, the clubs and Xylem have already reached more than 1 billion people through water awareness, education and volunteerism initiatives that advance their shared mission to create a more sustainable world. In this next phase, the partnership aims to accelerate action on critical water challenges by driving a further 100 million people to participate in water-related initiatives in their communities.
Roel de Vries, City Football Group’s Group Chief Operating Officer, said: “We’re delighted to be able to announce the extension of the partnership with Xylem today. Over the last four years, we have been able to successfully combine our place in the world of football with Xylem’s expertise in water education, to impact a huge number of people globally. Using the voice and influence of Manchester City, NYCFC and Mumbai City, we will continue to raise awareness and change behaviours around sustainable approaches. We look forward to continuing this work over the coming years.”
“When it comes to solving major challenges, our voices are more powerful together,” said Patrick Decker, President and CEO of Xylem. “That’s why one of the many ways Xylem advances water security is by engaging external stakeholders to put water on the agenda in new ways and venues. Through our partnership, we are creating a unique and powerful platform to connect with millions of fans around the world, spark conversation on water challenges and solutions – and inspire widespread action. We’re energized by the opportunities that lie ahead, and the potential to accelerate progress in our mission to solve water.”
The United Nations estimates that 3.2 billion people will live in severely water-scarce areas by 2050, if global warming continues at current projections1 . The three clubs and Xylem are elevating water within the global conversation on climate change through activities and dialogue that educate communities on the value of water, and projects to improve water and sanitation access.
Over the last four years, the partnership has empowered a global network of over 500 young community football leaders to deliver life-saving water awareness, education, and access to over 20,000 children in 8 countries across all continents. Delivered collaboratively with CFG’s global charity initiative Cityzens Giving, these projects combine football and WASH education with infrastructure upgrades using Xylem technology and expertise.
In 2021, Xylem and Manchester City joined forces with PUMA to launch the world’s first sports jersey dedicated to raising awareness of water challenges. The jersey was made using a special dope dye manufacturing process that reduces water consumption. The initiative brought together a diverse set of athletes across Manchester City men's, women's and academy teams to support football and safe water projects around the world.
Xylem will also play a central role in enabling the sustainability ambition of the wider City Football Group’s plans to make its global operations carbon neutral and water positive by 2030. Through technology and consultative support, Xylem will support the development of water usage and discharge strategies to increase efficiency and reduce waste on existing and future estate developments.
About Manchester City Football Club
Manchester City FC is an English Premier League club initially founded in 1880 as St Mark’s West Gorton. It officially became Manchester City FC in 1894 and has since then gone onto win the European Cup Winners’ Cup, seven League Championship titles, including six Premier League titles (2012, 2014, 2018, 2019, 2021, 2022), and six FA Cups. Manchester City FC is one of ten clubs comprising the City Football Group and counts New York City FC and Melbourne City FC among its sister clubs.
Under manager Pep Guardiola, one of the most highly decorated managers in world football, the Club plays its domestic and UEFA Champions League home fixtures at the Etihad Stadium, a spectacular 55,000 seat arena that City have called home since 2003. Today, the Stadium sits on the wider Etihad Campus, which also encompasses the City Football Academy, a state-of-the-art performance training and youth development facility located in the heart of East Manchester. Featuring a 7,000 capacity Academy Stadium, the City Football Academy is also where Manchester City Women’s Football Club and the Elite Development Squad train on a daily basis and play their competitive home games.
For more information, please visit www.mancity.com
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com .
1 https://www.unwater.org/water-facts/climate-change/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005235/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom